An update from Lytix Biopharma AS ( (DE:6BG) ) is now available.
Lytix Biopharma AS has announced the release of its fourth quarter 2024 financial results, scheduled for February 13, 2025. The company will host a live webcast featuring its CEO and CFO to discuss the financial outcomes and provide insights into future operations. This announcement highlights Lytix’s commitment to transparency and may impact its positioning within the biotech industry, potentially influencing stakeholder confidence.
More about Lytix Biopharma AS
Lytix Biopharma AS, based in Oslo, Norway, is a clinical-stage biotech company specializing in immuno-oncology. It focuses on developing innovative technology derived from host-defense peptide molecules, with its leading product, LTX-315, being a pioneering oncolytic molecule designed to enhance anti-cancer immunity. The company offers a pipeline of treatments applicable to various cancer indications and settings, both as standalone and combination therapies.
YTD Price Performance: -3.33%
Average Trading Volume: 2,166
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €33.2M
Learn more about 6BG stock on TipRanks’ Stock Analysis page.